Abstract
Nucleolin (NCL) is one of several potential molecular biomarkers that have been suggested as predictors for pediatric intracranial ependymomas. However, few studies have assessed whether NCL is an optimal prognostic marker to predict outcome in pediatric intracranial ependymoma. Thus, this systematic review and meta-analysis aimed to examine the prognostic role of NCL in predicting the outcome of patients with intracranial ependymoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
